Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Santhera Pharmaceutical Holding AG

+ Add to Watchlist

SANN:SW

97.60 CHF 2.15 2.16%

As of 11:43:40 ET on 04/20/2015.

Snapshot for Santhera Pharmaceutical Holding AG (SANN)

Open: 98.35 Day's Range: 97.50 - 100.00 Volume: 13,741
Previous Close: 99.75 52wk Range: 3.50 - 119.00 1-Yr Rtn: +2,611.11%

Stock Chart for SANN

No chart data available.
  • SANN:SW 97.60
  • 1D
  • 1M
  • 1Y
99.75
Interactive SANN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SANN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SMI -
Earnings Per Share (CHF) (ttm) -1.6017
Est. EPS (CHF) (12/2015) -2.3200
Est. PEG Ratio -
Market Cap (M CHF) 479.38
Shares Outstanding (M) 4.91
30 Day Average Volume 19,219
Price/Book (mrq) 67.6406
Price/Sale (ttm) 177.6605
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/28/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SANN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for SANN

Santhera Pharmaceuticals is a drug discovery and development company. The Company focuses on the discovery, preclinical and clinical development, and commercialization of pharmaceuticals for neuromuscular and metabolic diseases.

Martin GertschChairmanThomas MeierChief Executive Officer
More Company Profile & Key Executives for SANN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil